Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that enrollment in the diabetic kidney disease cohort of its Phase 2 REDUX chronic kidney disease study is complete, with all participants now on treatment. Additionally, 50% enrollment has been achieved in the IgA Nephropathy and African Americans cohorts. This study aims to assess the safety and efficacy of DM199 in approximately 90 participants across three cohorts. Positive results from earlier studies have raised expectations for topline results, anticipated in Q2 2021.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has received regulatory feedback from the FDA regarding its product candidate DM199 for treating acute ischemic stroke (AIS). The FDA's written responses, following a Pre-IND meeting, support the proposed design of a Phase 2/3 adaptive trial with a primary endpoint based on the modified Rankin Scale at day 90. The trial aims to enroll 300-350 participants and assess DM199's safety and efficacy. DiaMedica plans to file an IND submission soon, addressing a significant treatment gap for AIS patients within a 24-hour window.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Growth Conference. The chat is scheduled for November 23, 2020, at 10:00 AM ET and available until December 3, 2020. One-on-one meetings can be requested through Piper Sandler on December 1, 2020. A replay of the chat will be accessible via the Investors section of DiaMedica's website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls and CFO Scott Kellen will participate in the Craig-Hallum Alpha Select Conference on November 17, 2020. The conference will be held virtually due to social distancing measures amid the Covid-19 pandemic. Interested institutional investors should coordinate with their Craig-Hallum representative to arrange meetings. DiaMedica is focused on developing innovative treatments for chronic kidney diseases and neurological disorders.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has provided a business update and financial results for Q3 2020. Enrollment continues in the Phase II REDUX trial for DM199, targeting chronic kidney disease (CKD), but faces challenges due to COVID-19. 49 subjects are enrolled, with expectations for rapid enrollment in Cohort III. The FDA accepted a Type B meeting request regarding DM199 for acute ischemic stroke. A $23 million public offering was completed, bolstering cash reserves to $30.6 million. R&D expenses increased to $2.2 million, while total other income decreased to $128,000.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2020 financial results after market close on November 4, 2020. A conference call to discuss these results will be held on November 5, 2020, at 7:00 AM CT. Investors can join the call via dial-in or webcast, with replay options available until November 12, 2020. DiaMedica is focused on developing treatments for chronic kidney diseases and neurological disorders.